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Chemoprevention Researchers Look for
Ways to Halt the Process of Carcinogenesis
by Mariann Crapanzano

ears before the disease
develops, genetic
alterations are present
in the cells that will
become cancer. The body is
unable to repair the damage,
and the altered cells elude the
immune system. Further genetic
changes occur, perhaps caused
by exposure to carcinogens.
The cells divide, and over time,
a malignancy develops.

Y

The discovery of that malignancy
h as always marked the beginning of
treatment. But understanding the
multiple steps to cancer development
has inspired investigation of chemo,
prevention-the use of natural or
synthetic agents to interrupt or reverse
the process of carcinogenesis-and is
changing the way some researchers
think about cancer.
"Think of it as you do a chronic
disease, like hypertension or diabetes,"
said Waun Ki Hong, M.D., professor,
chairman of the Department of Tho,
racic/Head and Neck Medical Oncol,
ogy, and head of the Division of Cancer
Medicine at The University of Texas

(Continued on next page)

Fifteen years ago, Dr. Waun Ki Hong ,
head of the Division of Cancer Medicine ,
led a study showing that chemoprevention
agents could interrupt the progression of
premalignant lesions to cancer.
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Chemoprevention Research
(Continued from page 1)
M. D. Anderson Cancer Center. "The
treatment controls the disease. You may
not entirely eliminate the precancerous
cells, but you can undermine their
growth, so it will take a longer time
for the cancer to develop."
Retinoid studies
Multistep carcinogenesis, the
stepwise development of cancer, was
recognized years ago in epithelial
cancers and provided the framework
for Dr. Hong's early studies of retinoids,
synthetic and natural derivatives of
vitamin A, to interrupt the progression
of oral premalignant lesions. In 1986,
Dr. Hong and other investigators at
M. D. Anderson reported in the New
England Journal of Medicine that high,
dose 13,cis,retinoic acid substantially
reduced the size of the lesions in 67%
of the patients who had them and

produced histologic responses in more
than half of the patients treated. This
study provided proof that pharmacologic
agents could alter the progression of
premalignant lesions to cancer.
Dr. Hong, together with Scott M.
Lippman, M.D., professor and chairman
of the Department of Clinical Cancer
Prevention, and others at M. D.
Anderson, later demonstrated that
13,cis,retinoic acid was effective in
preventing second primary tumors
in patients who had previously been
successfully treated for primary cancers
of the head and neck. Patients with
these cancers have an increased risk of
developing second primary tumors, in
part because of a phenomenon known
as field carcinogenesis: exposure to a
single carcinogen, such as tobacco,
causes different genetic alterations in
epithelial tissues throughout an entire

PROTOCOLS
Chemoprevention
Clinical Trials

•

•

Randomized chemoprevention trial
with fenretinide (4-HPR) in superficial
bladder cancer (1D95-236). Physician:
H. Barton Grossman, MO.
Patients in this phase Ill trial must
have solitary or multifocal superficial
transitional cell carcinoma of the
bladder that is either newly diagnosed
or secondary in patients who have
been primary tumor-free for more
than a year. Newly diagnosed bladder
tumors must have been resected less
than four weeks prior to study entry.
Women must not be pregnant at the
time of enrollment and must use a
contraceptive during the trial and
for one year afterwards.
Phase II study of eflornithine (DFMO)
in patients with Barrett's esophagus
with dysplasia (DM98-204). Physician:
Frank A. Sinicrope, MO.
Patients 18 years of age and older
with histologically confirmed or sus-

2 / OncoLog

I

I

pected Barrett's esophagus with any
degree of mucosal dysplasia are eligible
for treatment on an outpatient basis in
this study. Participants with any prior
malignancy must have no evidence of
disease by clinical assessment and
imaging studies at study entry and
cannot have received chemotherapy
or radiation therapy for six months prior
to study entry. All patients must consent
to four esophagastroduodenal exams
and esophageal biopsies for histologic
evaluation.

Clinical trials of chemopreventive
agents in progress at The University of
Texas M. D. Anderson Cancer Center
include the following.

•

field, such as the aerodigestive tract.
"For head and neck cancers,
retinoids are quite promising agents
in controlling precancerous cells,"
said Dr. Hong.
Retinoids have toxic side effects,
however, and the inhibitory effects
shown in the 1986 study as well as in
other studies did not continue after the
treatment was stopped. According to
Dr. Lippman, this suggests that although
13,cis,retinoic acid blocks the progression from genotypic to phenotypic
changes, the molecular genetic changes
in the tissue remain, leading to recur,
rence in the absence of the drug.
Nonetheless, the benefits seen thus
far are substantial, and research on
retinoids forges ahead. A current study
led by Dr. Hong will determine whether
low,dose 13,cis,retinoic acid-which
should have fewer and less severe side

Induction of biochemoprevention
followed by fenretinide versus placebo
maintenance for advanced laryngeal
dysplasia (1D98-017). Physician: Waun
Ki Hong, M. D.
Participants must have measurable
laryngeal premalignant lesions that
can be biopsied and histologic proof
of moderate or severe dysplasia or
carcinoma in situ. Patients may have
received prior retinoid therapy but
must have discontinued therapy at
least three months prior to study
entry. Patients receiving treatment
with concurrent chemotherapy, immunotherapy, radiotherapy, or megadose
vitamins will not be eligible. Those
using tetracycline or its derivatives
or oral anticoagulants may not
enroll in this study.

•

Study of tamoxifen and raloxifene
(STAR) for the prevention of breast
cancer (NSABP99-2}. Physician:
Therese B. Bevers, MD.
Postmenopausal women who are 35
years old or older and are at increased
risk for developing breast cancer are
eligible for this randomized study.
Women are considered to be at
increased risk if they have a personal
history of lobular carcinoma in situ or
an estimated five-year risk of developing invasive breast cancer of at least
1. 7% as established by the modified
Gail model. A general physical examination , including a breast exam
showing no evidence of malignancy,
is required within 180 days prior to
randomization. Women using estrogen,
progesterone, oral contraceptives,
androgens, or similar drugs are not
eligible unless they discontinue use
three months prior to randomization.
Women who have had prior invasive
breast cancer of any type or intraductal
carcinoma in situ are not eligible.

•

A phase II study of adenovirus ONYX015 administered by mouthwash as a
chemopreventive agent and for the
treatment of oral dysplastic lesions
(HNS99-140). Physician: Vassiliki
Papadimitrakopoulou, MO.
Patients 18 years or older with a

effects-given over three years is
effective in preventing second primary
tumors in patients cured of an initial,
early,stage head and neck cancer.
Retinoic acid is also a key compo,
nent in a biochemoprevention regimen
that Drs. Hong and Lippman and others
at M. D. Anderson developed and are
currently investigating. The combin a,
tion of 13,cis,retinoic acid, alph a,
tocopherol (vitamin E), and interferon
reversed the progression of advan ced
premalignant laryngeal lesions in one
study and has shown promise against
recurrent squamous cell cancers of
the skin, said Dr. Lippman.
Retinoids alone number in the
thousands and make up just one class
of the many potential chemopreventive
agents that are still under invest igation.
Some other agents are nonsteroidal
anti,inflammatory drugs (N SAIDs),

carotenoids, alpha,difluoromethyl,
ornithine (DFMO) , vitamins D and E,
and selenium. These and other com,
pounds are be ing evaluated through
M. D. Anderson's multidisciplinary
chemoprevention program, which was
largely developed by Dr. Hong in the
field of head and neck cancer and has
expanded to include thoracic, breast,
colorectal, prostate, bladder, and
skin cancers.

Chemoprevention in
breast and colon cancers
A lthough chemoprevention is still
in its infancy, it h as already commanded
considerable atten tion . Tamoxifen , a
selective estrogen,receptor modulator,
took center stage as a chemopreventive
agent in late 1998 when it became the
first drug to be approved by the U .S.
Food and Drug Administration (FDA)

for use in reducing the occurrence of
breast cancer in women at high risk for
the disease. In the N ation al Surgical
Adjuvant Breast and Bowel Project
Breast C ancer Prevention Trial, the
incidence of invasive breast cancer in
women who took tamoxifen was
reduced by 49%, and o ther studies of
the drug have shown impressively
consistent results. This success and
subsequent FDA approval of tamoxifen
signaled a shift in the approach to
breast cancer.
Another more recent milestone in
the fie ld of chemoprevention was the
FDA approval of the N SAID celecoxib
(as a supplement to routine manage,
ment) to reduce the number and size
of colorectal polyps in patien ts with
familial adenomatous polypos is (FA P).
Patients with FA P, wh o h ave a germline
(Continued on page 4)

PROTOCOLS
clinical diagnosis of oral dysplasia
but no evidence of malignancy or
open ulceration of the oral mucosa are
eligible for this study. Return visits will
be daily for five days every four weeks
with the four-week cycle repeated up to
12 times. Women who are pregnant or
lactating are not eligible, and study
participants must use a contraceptive.
•

A two-arm , phase II chemoprevention
study of celecoxib (Celebrex) with or
without DFMO in patients with familial
adenomatous polyposis (ID00-109).
Physician: Frank A. Sinicrope, M.D.
Eligible subjects must be between
the ages of 18 and 65 and have a
confirmed diagnosis of familial
adenomatous polyposis. Endoscopic
evaluation of the colon or rectum must
be possible, and patients must have at
least five polyps at baseline. Individuals
with hypersensitivity to aspirin or
aspirin-related drugs, cyclooxygenase
(COX)-2 inhibitors, or sulfonamides, a
prior history of pelvic radiation , or
significant hearing loss are not eligible.
Participants must consent to two
colonoscopies, one esophagogastroduodenoscopy (a second one would be
required only if duodenal disease was
present at baseline) , and three audiograms during the six-month study
period and must agree to refrain from

using aspirin or aspirin-related drugs
while on the study.
•

•

A phase II double-blind, placebocontrolled , randomized study of
celecoxib (SC-58635) in oral premalignant lesions (ID00-131) . Physician:
Vassiliki Papadimitrakopou/ou, M.D.
Participants must be older than 18
years and have a histologically confirmed early or advanced oral premalignant lesion that is at least 8 mm in
diameter and has not been biopsied in
the six weeks prior to study entry. Study
participants must be willing to abstain
from chronic use of all nonsteroidal antiinflammatory drugs (NSAIDs) and COX2 inhibitors, excluding low-dose aspirin
(s 100 mg per day) and must not be
taking ~ 60 mg/day of beta-carotene
alone or in a supplement within two
weeks prior to study entry and for the
duration of the study. Patients who have
received chemotherapy, immunotherapy,
hormonal therapy (other than hormone
replacement therapy for menopause) , or
radiation therapy within three weeks
of study entry or who need concurrent
treatment with any of these therapies
will not be eligible.
A phase 11 study of colorectal aberrant
crypt foci screening, regression , and
prevention in high-risk patients (ID01-

454). Physician: Frank A. Sinicrope,
M.D.
Men and women between the ages
of 40 and 80 with prior or current
colorectal adenomas or prior colorectal
cancer will be recruited to this study.
At baseline, all eligible participants
must have at least five colorectal
aberrant crypt foci documented by
chromoendoscopy. Patients with a
history of gastroduodenal ulcers, prior
pelvic radiation , a known diagnosis of
hereditary colon cancer, or inflammatory bowel disease will be excluded.
Hypersensitivity to aspirin or aspirinrelated drugs, COX-2 inhibitors, or
sulfonamides renders patients ineligible. Patients must agree to refrain
from using all nonsteroidal antiinflammatory drugs (NSAIDs) while
on study and must consent to two
colonoscopies. •
FOR MORE INFORMATION about these clinical trials'
physicians or patients may call the M. D. Anderson
Information Line. Those within the United States
should call (800) 392, 1611; those in Houston or
outside the United States should call (713) 792,
6161 . Visit the M . D. Anderson Cancer
Center clinical trials Web site at http://
www.clinicaltrials .org for a broader listing
of treatment research protocols .

OncoLog / 3

Chemoprevention Research
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"One of the goals is to find an agent or
combination that will control the polyp
growth and progression so that we can
delay surgery (colectomy) to allow the
patient to reach physical and
psychological maturity."
- Frank A. Sinicrope, M.D., associate professor
and chairman ad interim, Department of
Gastrointestinal Medicine and Nutrition

mutation in the adenomatous polyposis
coli gene, develop innumerable adeno,
matous polyps in the colon and have a
nearly 100% risk of developing colon
cancer by their fifth decade of life.
Celecoxib selectively inhibits the
cyclooxygenase (COX),2 enzyme,
whereas conventional NSAIDs inhibit
both COX, 1 and COX, 2 isoforms.
Inhibition of COX, 1 is believed to
account for gastrointestinal and other
side effects of NSAIDs.
The FDA approval of celecoxib as
a pharmacologic adjunct in the manage,
ment of FAP was based largely on the
results of a multi,institutional, placebo,
controlled study headed by Gideon
Steinbach, M.D., Ph.D. (now at the
University of Washington), Patrick M.
Lynch, M.D., J.D., an associate professor
in the Department of Gastrointestinal
Medicine and Nutrition, and Bernard
Levin, M.D., vice president for Cancer
Prevention at M. D. Anderson. This
study showed a mean 28% decrease
in the number of colorectal polyps in
patients who took 400 mg of celecoxib
twice daily for six months.
"This important study demonstrated
the chemopreventive efficacy of a selec,
tive COX, 2 inhibitor and has led to the
development of subsequent studies in
FAP as well as in patients with sporadic
adenoma," said Frank A. Sinicrope,
M.D., associate professor and chairman
ad interim of the Department of Gas,
trointestinal Medicine and Nutrition.
The ongoing quest for even more
effective agents or combinations of
agents to help clinically manage colonic
polyps is especially significant in
patients with FAP because in addition
to the cancer risk, they face grave
quality,of,life issues, with many under,
4 I OncoLog

going a prophylactic colectomy at an
early age. Dr. Sinicrope and others at
M. D. Anderson, together with
researchers from the Cleveland Clinic
and St. Mark's Hospital in London,
England, hope to build on the data
from the celecoxib study. In
a National Cancer Institute (NCI)sponsored trial, they are comparing
the effects of combined celecoxib
and DFMO with celecoxib alone in
patients with FAP. Animal studies
have shown that the combination
of an NSAID and DFMO is more
effective than either drug alone.
"One of the goals," said Dr.
Sinicrope, "is to find an agent or
combination that will control the polyp
growth and progression so that we can
delay surgery ( colectomy) to allow the
patient to reach physical and psycho,
logical maturity." The other goal, he
added, is to control the polyps in the
rectum after a colectomy is performed
and to prevent subsequent cancer.
Dr. Sinicrope is the principal
investigator in another NCl,sponsored
study to determine whether sulindac
or aspirin (both NSAIDs) or ursode,
oxycholic acid, a drug sometimes used
to treat gallstones, can reduce the
number of aberrant crypt foci in the
colorectums of patients with a history
of colonic polyps or colon cancer.
Aberrant crypt foci are mucosal lesions
in the colorectum that may be precur,
sors to precancerous polyps and can be
visualized during a colonoscopy using
a dye to spray the mucosa.

Mechanisms of action
The exact mechanisms by which
chemopreventive agents work are
not fully understood and are the

subject of extensive investigation.
Reuben Lotan, Ph.D. , professor and
deputy division head for research,
Division of C ancer Medicine, has
played a key role in m any studies by
leading the laboratory analyses.
Multistep carcinogenesis begins
with initiation, said Dr. Lotan, a genetic
change in the cell that, if not repaired,
persists in the cell's progeny. The body's
complex DNA repair mechanism fre,
quently does repair the damage, and most
initiated cells do not develop into cancer.
"Many cells are initiated every
day through inadvertant exposure to
environmental physical and chemical
carcinogens," Dr. Lotan said, "and our
bodies are constantly repairing the
damage."
But if the DNA repair is incom,
plete-or new genetic errors are intro,
duced during the repair process-and
the genetically altered cell escapes the
immune system, said Dr. Lotan, the
abnormal cells proliferate, a process
often promoted by repeated exposure
to carcinogens. This promotion stage
may last 20 years or longer before the
cells become malignant. Thus, multistep
carcinogenesis provides both time and
multiple opportunities to intervene in
the progression of the disease.
Some agents are studied for their
ability to prevent initiation, but the
two principal modes of action by
many agents are growth inhibition and
programmed cell death, or apoptosis.
A single type of agent may have more
than one mechanism. For example,
NSAIDs are known to induce apoptosis
by inhibiting the C OX enzyme, which
is highly expressed in many colorectal
lesions. But recent research at M. D.
Anderson has shown that some
NSAIDs trigger apoptosis in cells that
do not express the C OX enzyme by
increasing the expression levels of
15,lipoxygenase, indicating that the
chemopreventive effect of these agents
can be COX,independent.
Retinoids affect the expression of
genes that regulate cell growth and
differentiation or cell death, generally
acting through retin oid receptors in
the cell's nucleus that are abnormally
expressed in various cancer types, Dr.
Lotan said. Laboratory analyses in the

Chemoprevention Trial Targets Former Smokers

F

by Noelle Heinze
inding a way to prevent lung
cancer from developing after
healthy lung tissue has been
exposed to carcinogens and genetic
changes have occurred is the challenge
faced by researchers designing
chemoprevention trials for former
smokers. In an ongoing clinical trial
at The University of Texas M. D.
Anderson Cancer Center, doctors
and researchers in the Department
of Thoracic/Head and N eek Medical
Oncology are studying the effects of
retinoic acid on precancerous cells in
both current and former smokers to
try and reverse or delay the cellular
processes that may lead to the development of lung cancer.
"Once lung tissue is exposed to
carcinogens, an initiation phase occurs,
which means that some genetic changes
occur and then progress into multiphases of premalignant lesions that then
become cancer," said Waun Ki Hong,
M.D., chairman of the Department
of Thoracic/Head and Neck Medical
Oncology and head of the Division of
Cancer Medicine at M. D. Anderson.
Targeting precancer cells for treatment
may delay the onset of cancer in
particular people. "If you can eliminate
the precancer cells, that's wonderful;
if not, then you may undermine the
precancer cells and even kill some of
these cells," Dr. Hong explained.
Retinoids, which act by binding to
a specific set of receptors and inducing
differentiation in cells that have lost
normal regulatory mechanisms, have
shown the ability to suppress lung

carcinogenesis in animal models,
and clinical trials are being conducted
to discover the effects of retinoids
on human lung tissue.
In one such trial, current and former
smokers are randomly assigned to
receive 13-cis-retinoic acid, alone or in
combination with alpha-tocopherol, or
a placebo for three months. Although
former smokers are the subjects in this
study, current smokers are enrolled
because patients who quit smoking
sometimes start smoking again, and it
is important to know the risks to these
patients. "Carcinogens and chemopreventive agents can become in effect
collaborative," said Dr. Hong. "They
can actually work together and induce
adverse reactions."
Also, chemopreventive agents may
not be very effective for people who
continue to smoke. "We think that
former smokers are a great target for
chemoprevention because we don't have
to really worry about counteracting the
tobacco carcinogens' effects on the
chemopreventive agent," said Dr. Hong.
About 240 patients are currently
enrolled in the chemoprevention trial.
A bronchoscopy is performed before
patients are accepted into the study to
identify any precancerous or cancerous
cells developing in the lungs. A chest
x-ray is also performed to see if any
mass is visible.
"Patients enrolled in the study
will be those who have some cellular
changes that indicate that they are at
high risk but who do not have cancer,"
said Michele Glover, a research nurse in
the Department of Thoracic/Head and
Neck Medical Oncology.

biochemoprevention trial of 13-cisretinoic acid, alpha-tocopherol, and
interferon in patients with advanced
laryngeal lesions documented the
reappearance of a functional, wild-type
p53 tumor-suppressor gene in posttreatment tissue samples from some patients
whose pretreatment biopsies contained
a mutant p53 gene. This indicates that
the biochemoprevention actually
eliminated the abnormal clonal cells
in these patients.

At this point in its development,
chemoprevention controls disease by
interrupting carcinogenesis and extending the latency period or the delay
between the initiation of the cells and
the development of cancer. The results
are very encouraging, although more
research is needed to weigh the risks
and benefits of extended chemoprevention therapy. Or. Lippman
said that in mice, which live about
18 months, chemoprevention has been

After three months, the study is
unblinded to see which patients received the drug, if the results of bronchoscopy have changed, and if the
change was significant. Patients who
received the placebo are given the
opportunity to take 13-cis-retinoic
acid for three months, and then a
final bronchoscopic examination is
performed, and the results are compared
with those of the first and second
examinations for any changes. "Patients
will receive some benefit from the study
one way or another," said Glover. "They
may not get the luck of the draw at the
beginning, but eventually all patients
will be treated."
According to Dr. Hong, the study
is important because it will demonstrate
whether chemoprevention with 13-cisretinoic acid is capable of eliminating
genetic or phenotypic changes in the
airway, which could in turn delay
or prevent the development of lung
cancer.
Dr. Hong's group is also conducting
molecular, biomarker, and epidemiological studies to establish a model to
identify individuals at high risk for lung
cancer development who could benefit
the most from chemopreventive therapy.
"We are working very hard at
developing a risk model," Dr. Hong
said. "Once we establish the model and
get a profile of patient characteristics,
a computer could tell a patient's risk
of getting lung cancer in 5 or 10 years.
That is something we are struggling
with." •
FOR MORE INFORMATION' contact
Dr. Hong at (713) 792-6363 .

shown to extend the latency for as long
as three months. If this result can be
translated to humans, said Dr. Lippman,
chemoprevention in some individuals
may delay the development of cancer
long enough to effectively prevent it. •
FoR MORE INFORMATION, contact Dr.
Hong at (713) 792-6363 , Dr. Lippman
at (713) 745-3672, Dr. Levin at (713)
792-3900, Dr. Sinicrope at (713) 7928566, or Dr. Lotan at (713) 792-8467.
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Your opinions are important to us. Please take a few moments to complete the
survey below if you haven't before. Return it to OncoLog Survey, Department of
Scientific Publications-Box 234, M. D. Anderson Cancer Center, 151 5 Holcombe
Boulevard, Houston, Texas 77030. Or simply fax your answers to (713) 794-1370.
Your responses will help us ensure that OncoLog continues to meet your cancer
information needs. Thank you!

We Want to
Hear from You

IV. Please answer the following
questions.

I. Please respond Yes or No to the following statements.
Yes

1. I read most issues of OncoLog that I receive.
2. I read OncoLog on the Internet
(www3.mdanderson.org/- oncolog) .

3. OncoLog is useful to me in my practice.
4. I photocopy House Call (patient education page)
articles and distribute them to my patients.
5. I have referred a patient to M. D. Anderson.
6. I have referred a patient to M. D. Anderson because
of something I read in OncoLog.

No

Yes
Yes

No
No

Yes
Yes

No
No

Yes

No

1 . How long have you been receiving
OncoLog?

2 . After readi ng OncoLog, I (circle one) :
a. Save it for future reference
b. Throw it away
c. Make it available to colleagues or
patients

II. Please indicate the overall quality (e.g., importance, usefulness,
and appeal) of the following OncoLog regular features.

3. W hat would you like to see more of in
OncoLog?

Fair

Good

Excellent

Full-length main articles

2

3

4

One-page prevention articles

2

3

4

House Call (patient education page)

2

3

4

Dialog (editorial on back page)

2

3

4

Protocols

2

3

4

Compass (quarterly insert of treatment guidelines)

2

3

4

Poor

4. W hat would you like to see less of?

Please comment on any features that you rated especially low or high:

5. Comments about content, writing , or
design of OncoLog:

Ill. Indicate your level of interest in the following topics.

V. Demographic information :

Not
Interested

Neutral

Mildly Moderately Strongly Extremely
Interested Interested Interested Interested

Ag e
Sex (circle one)

M

F

pec1a ty
Cancer prevention and detection

2

3

4

5

6

Cancer screening guidelines

2

3

4

5

6

Cancer diagnostic guidelines

2

3

4

5

6

Cancer treatment guidelines

2

3

4

5

6

Location of practice (circle one) :
Rural

Urban

Suburban

Other

Type of practice (circle one):

Multidisciplinary care options for
patients at M. D. Anderson

2

3

4

5

6

Case reports including workup,
staging, and treatment selection

2

3

4

5

6

Group

2

3

4

5

6

Ethical issues related to
cancer care

2

3

4

5

6

M. D. Anderson departments
or programs

2

3

4

5

6

Solo

Institution

Other

VI. Personal information (optional):
Name

Social or psychological aspects
of patient care
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Years in practice

Address

Phone
E-ma il

HPV and Cancer: What Every
Woman-and Man-Should Know
he news hits a woman
hard-the results of
her Pap test are
abnormal , and the
diagnosis is cancer of the cervix.
What she hears next may sur-prise her. The agent that caused
the disease is a sexually trans-mitted infection known as hu-man papillomavirus (or HPV).
For women and men alike,
this virus and its effects can
have far--reaching implications.
More than 30 types ofHPV-more
than 100 have been identified-are
transmitted through sexual contact, and
approximately half of these have been
linked to cancer. For years recognized as
the major cause of cancer of the cervix
( the opening to the uterus), HPV has
also been associated with some cancers
of the vulva, vagina, anus, penis, and
oropharynx ( the middle throat, including
the base of the tongue and the tonsils).
HPV infections cause symptoms in
some but not all patients. Some types
of sexually transmitted HPV, including
HPV types 6 and 11, cause wart,like
lesions in the genital tract or anus of
both men and women but rarely lead
to cancer. The warts may appear within
- weeks_oLsexuaLcontact with an HPV
infected person or may appear years
later, if at all. Other types of the virus,
including HPV types 16, 18, 31, 33, and
35, can cause growths that are usually
flat and difficult to see and can lead to
the development of cancer. A test for
the viral DNA in the affected tissue can
reveal the type of HPV that is present.
In women, HPV infection can cause
abnormal changes in the outermost
layer of cells ( the epithelium) covering
the cervix. These abnormal cells,
known as squamous intraepithelial
lesions (SILs) (or sometimes dysplasia or
cervical intraepithelial neoplasia), are
not cancerous, but they are precursors to
cancer. SILs can be detected by a Pap

type of HPV, such as HPV, 16, increases
the risk that the SILs that are caused by
HPV will develop into cancer. Smoking,
the use of oral contraceptives, infection
1. Commencing sexual
with oth er sexually transmitted diseases
intercourse at a young age
or with the human immunodeficiency
(16 years or younger)
virus, or having many children may act
2. Having many sexual partners
as cofactors with HPV and thus play a
role in the progression of SILs to cancer.
There is no medical cure for HPV
Possible cofactors
infection, but SILs and the genital warts
with HPV
that are caused by HPV infection can
be treated. A patient whose Pap test is
The following may act as coabnormal is referred for colposcopy
factors with HPV and thus play a
(examination of the cervix and vagina
role in the development of cancer.
under a magnifying lens through an
instrument called a colposcope). The
1. Smoking
doctor takes biopsy specimens from
2. Oral contraceptives
abnormal areas, and the tissue is exam,
3. Infection with other sexually
ined to determine the grade of the
transmitted diseases or with
abnormality and whether cancer
HIV
is present. A high,grade SIL may be
4. Giving birth to many children
treated with a laser, LEEP (loop electro,
surgical excision procedure), cryosurgery
test performed during a gynecologic
(use of cold to destroy the tissue),
examination.
surgical excision ( including conization,
Many low,grade dysplasias regress
the removal of a cone,shaped zone of
and become normal over a period of
tissue around the abnormal cells), or in
months or years. In these patients, the
some cases chemopreventive agents.
Pap test may become normal, and the
Genital warts may be treated with some
HPV is considered to be latent or
of these same procedures.
possibly to have been eliminated by the
Thanks to the detection of precancer,
patient's immune system. It is believed
ous cells by the Pap test and the treat,
that a latent infection can be reacti,
ment of these cells, the incidence of
vated years after the patient's initial
cervical cancer has declined. Receiving
exposure to HPV. In patients who
regular gynecologic examinations and
develop cervical cancer, tne HP\t_ _ __,Pap-test:5-areJmportant steQ_S_in_ th_e_ _ ___J_
persists or is reactivated, and the SILs
diagnosis and treatment of SILs
progress over many years, becoming
and ultimately in the prevention of
increasingly abnormal and invading
gynecologic cancers. •
deeper and deeper levels of the epithe,
lium. High,grade SILs include abnormal
For more information, contact
cells that extend through the full
your physician or contact the
thickness of the epithelium, also known
M.
D. Anderson Information Line:
as carcinoma in situ, an early form of
cervical cancer.
({) (800) 392-1611 within
Risk factors for HPV infectionthe United States, or
and thus for cervical cancer-include
({) (713) 792-6161 in Houston
commencing sexual intercourse at a
and outside the United States .
young age ( 16 years or younger) and
having many sexual partners, which
July/August 2001
increases the chance of exposure to
©200 1 The University of Texas
HPV. Also, infection with a high,risk
M. D. Anderson Cancer Center

Risk factors for
HPV infection
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Serving International Clients
Wendeline Jongenburger, M.B.A.
Director, International Programs
M. D. Ander n
Cancer Center
serve patients from
countrie around
the globe who eek
the be t hope for
urvival. But the e
international patients
and their familie al o
receive care that
extends beyond
treatment to meeting their communicati n,
cultural, and ocial need .
Eight perc nt of M. D. Ander on'
patient population come from abroad.
Of the e, half are fr m Latin Am rica,
while the re t come from all comer of the
world. Many arrive in Hou ton una
·
fortable, and i
ome patient com rom cu ture w ere
the word "cancer" i o taboo that it i not
openly discus ed. Other bear the tigma
that they are omehow being puni hed by
"catching" cancer. Many have philosophical
and religious beliefs that can et the tage
for ethical conflict with Western medical
practices, especially in regard to treatment
and end,of,life choice .
Understanding the need of M. D.
Anderson' international patients and
helping them feel at home is the responsi,
bility of International Programs, which
includes the International Patient Center
(IPC) and the Department of Language
A sistance. Before the patients arrive, the
IPC staff verifies that they meet the medical
clearance and financial requirement for
8 I OncoLog
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come to Hou ton to ee our cancer cent r.
By promoting education communica,
tion, and under randing, the International
Program taff help our international
patient and their familie find care com£ n
and hope thou and of mile from h me.

contact International
Programs at (713) 745, 45 .
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